



## **The Oncology Institute Announces Second Quarter 2022 Earnings Release Date and Conference Call**

July 19, 2022 12:01 PM EDT

CERRITOS, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ: TOI) today announced that the company will release its second quarter results after the market close on Tuesday August 9, 2022, to be followed by a conference call the same day 5:00 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13731004. The replay will be available until August 16, 2022.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at <https://investors.theoncologyinstitute.com/>.

### **About The Oncology Institute**

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 80+ employed clinicians and more than 600 teammates in 50+ clinic locations and growing, TOI is changing oncology for the better.

### **Contacts**

#### **Media**

The Oncology Institute  
Julie Korinke  
[juliekorinke@theoncologyinstitute.com](mailto:juliekorinke@theoncologyinstitute.com)  
(562) 735-3226 x 88806

Revive  
Michael Petrone  
[mpetrone@reviveagency.com](mailto:mpetrone@reviveagency.com)  
(615) 760-4542

#### **Investors**

Solebury Trout  
Maria Lycouris  
[investors@theoncologyinstitute.com](mailto:investors@theoncologyinstitute.com)